Aligos Therapeutics' Lead HBV Drug Shows Positive Data at EASL, Suggesting Functional Cure Potential
ALGS is trading near its 52-week low of $5.12 (11% above the low).
Summary
Aligos Therapeutics presented positive clinical and preclinical data for its lead HBV drug candidate, pevifoscorvir sodium, at the EASL Congress 2026. The data indicates the drug may reduce the cccDNA reservoir, potentially replacing current standard of care and contributing to a functional cure for chronic HBV. This follows recent FDA Fast Track Designation and a significant licensing deal for the drug. Despite these advancements, the company faces a 'going concern' warning with cash projected only into Q4 2026, making strong clinical progress for its core asset critical for its viability.
At the time of this announcement, ALGS was trading at $5.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.5M. The 52-week trading range was $5.12 to $13.69. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.